-
The Journal of the Association of... Jul 1980
Review
Topics: Adolescent; Adrenal Glands; Adult; Age Factors; Animals; Chemical Phenomena; Chemistry; Female; Humans; Kidney; Male; Pituitary Gland; Pregnancy; Prolactin; Sex Factors
PubMed: 7009537
DOI: No ID Found -
Hormones and Behavior Nov 2004Hyperphagia is a prominent component of the parental behavior repertoire in male and female ring doves and is necessary in order for parents to successfully provision... (Comparative Study)
Comparative Study
Hyperphagia is a prominent component of the parental behavior repertoire in male and female ring doves and is necessary in order for parents to successfully provision their growing young. Although previous studies implicate both prolactin and the endogenous glucocorticoid, corticosterone, in parental hyperphagia, the functional interactions between these two hormones in regulating changes in feeding activity have not been characterized. These studies examined the possibility that prolactin's orexigenic effects are mediated through the increased secretion of corticosterone. Twice-daily intracerebroventricular (icv) injection of prolactin increased plasma corticosterone concentration in non-breeding doves of both sexes, with males exhibiting more pronounced effects than females. To further test the importance of glucocorticoid signaling in prolactin-induced feeding responses, changes in food intake were investigated in icv prolactin-treated, non-breeding doves following icv infusion of the glucocorticoid receptor antagonist RU38486 or propylene glycol vehicle. No attenuation of prolactin-induced hyperphagia was observed in either sex following co-administration of RU38486 at a dose shown previously to block dexamethasone-induced feeding in doves. These findings suggest that elevated corticosterone titers in blood may contribute to the hyperphagia observed in response to prolactin, but corticosterone signaling through a mammalian-type glucocorticoid receptor is not essential.
Topics: Animals; Bird Diseases; Columbidae; Corticosterone; Feeding Behavior; Female; Hormone Antagonists; Hyperphagia; Injections, Intraventricular; Male; Maternal Behavior; Mifepristone; Paternal Behavior; Prolactin
PubMed: 15465537
DOI: 10.1016/j.yhbeh.2004.02.012 -
Neuro-Chirurgie 1981
Review
Topics: Animals; Humans; Hypothalamus; Pituitary Gland, Anterior; Prolactin
PubMed: 7024835
DOI: No ID Found -
Coeur Et Medecine Interne 1980
Review
Topics: Adenoma; Breast Neoplasms; Female; Humans; Male; Pituitary Neoplasms; Prolactin
PubMed: 7006896
DOI: No ID Found -
Danish Medical Bulletin Oct 1982
Review
Topics: Amniotic Fluid; Estrogens; Female; Humans; Hypothalamo-Hypophyseal System; Lactation; Pituitary Gland; Pregnancy; Prolactin; Thyrotropin-Releasing Hormone
PubMed: 6814828
DOI: No ID Found -
Bulletin de L'Academie Royale de... Jan 1973
Topics: Animals; Columbidae; Culture Techniques; Female; Fluorescent Antibody Technique; Growth Hormone; Histocytochemistry; Humans; Hypothalamus; Immune Sera; Male; Organ Culture Techniques; Pituitary Gland; Pituitary Gland, Anterior; Pregnancy; Prolactin; Rats; Tissue Extracts
PubMed: 4618506
DOI: No ID Found -
Journal de Gynecologie, Obstetrique Et... 1982The surgical treatment of prolactinomas protects against the complications that these tumours have, but by itself does not cure the infertility which is found in at most... (Review)
Review
The surgical treatment of prolactinomas protects against the complications that these tumours have, but by itself does not cure the infertility which is found in at most 50% of all cases. The value of radiotherapy is limited to those cases where there is a contra-indication for carrying out surgery and in the tumours that have been incompletely removed and when pregnancy is not desired. The principal drugs used to lower prolactin are the dopamine agonist, which is bromocriptine and the serotonin antagonist which is methergoline which is less powerful than bromocriptine. Bromocriptine brings about normal prolactinaemia and ovulation is re-established and menstruation returns in most cases of idiopathic hyperprolactinaemia and in many cases where hyperprolactinaemia is due to a tumour. It, in certain cases, has an antitumoral effect and can definitely cure some hyperprolactinaemias whether they are tumoral or not. So bromocriptine is the specific treatment of women whose sterility is due to hyperprolactinaemia and no teratogenic effect has been reported. The only complications that have occurred in pregnancies that have been induced by this drug have been growths in the tumours in women who have pituitary adenomata, but these complications are far less frequent and serious in cases of micro-adenomata. Since the antitumoral effect of bromocriptine has been discovered the indications for surgery have lessened but it is often all the same necessary. The medical treatment of adenomata can only be considered when strict supervision is going to be undertaken. Bromocriptine can also establish ovulation in a few categories where ovulation occurs in normoprolactinaemic women and it can also be used as a treatment for the premenstrual syndrome.
Topics: Anovulation; Bromocriptine; Female; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Premenstrual Syndrome; Prolactin
PubMed: 6754799
DOI: No ID Found -
Postepy Biochemii 2002
Review
Topics: Biotechnology; Homeostasis; Pituitary Gland; Prolactin; Protein Isoforms; Protein Processing, Post-Translational; Receptors, Prolactin; Reproduction; Signal Transduction; Tissue Distribution
PubMed: 12731395
DOI: No ID Found -
Ginekologia Polska Jan 1981
Review
Topics: Female; Fetus; Humans; Labor, Obstetric; Placenta; Postpartum Period; Pregnancy; Pregnancy Complications; Prolactin
PubMed: 7026376
DOI: No ID Found -
Breast Cancer Research and Treatment Nov 2007Prolactin is a polypeptide hormone that promotes normal breast proliferation and differentiation, but it is also implicated in the development and growth of mammary...
BACKGROUND
Prolactin is a polypeptide hormone that promotes normal breast proliferation and differentiation, but it is also implicated in the development and growth of mammary tumors. Mammographic density is a strong, independent predictor of breast cancer and, therefore, a potential surrogate indicator of breast cancer risk.
METHODS
To test the hypothesis that serum prolactin is positively related to mammographic density, we conducted a cross-sectional analysis of baseline data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Mammographic Density Study. Based on prior work, we further hypothesized that this association would be apparent only in women who had not recently used postmenopausal hormone therapy (HT).
RESULTS
In linear regression models adjusted for age, body mass index, race, smoking, alcohol use, parity and physical activity, among the 400 women who were not recent users of HT, prolactin was positively and statistically significantly associated with mammographic density (Beta log base 2 prolactin 0.0369 [95% CI: 0.0094-0.0645]. Thus, for each doubling of serum prolactin, there was an absolute increase in mammographic density of 3.69%. Additional adjustment for serum levels of estradiol, progesterone, sex hormone binding globulin and age at first pregnancy did not affect this result. There was no association between prolactin and mammographic density among the 169 participants who had recently used HT.
CONCLUSION
The correspondence between higher prolactin and higher mammographic density is consistent with prolactin's mitogenic properties and the associations between prolactin and breast tumor promotion. These results support the thesis that prolactin deserves investigation as a target for breast cancer risk reduction.
Topics: Estrogen Replacement Therapy; Female; Humans; Mammography; Middle Aged; Postmenopause; Prolactin
PubMed: 17260098
DOI: 10.1007/s10549-006-9454-y